Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Karl Brendel

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
CPT: Pharmacometrics & Systems Pharmacology|October 28, 2025
The Evolving Role of In Vitro-In Vivo Correlation in Model-Informed Drug Development: A Multi-Stakeholder PerspectiveMarylore Chenel, Sylvain Fouliard, Emma Hansson, et al.
Clinical Pharmacokinetics|March 3, 2007
Are population pharmacokinetic and/or pharmacodynamic models adequately evaluated? A survey of the literature from 2002 to 2004Karl Brendel, Céline Dartois, Emmanuelle Comets, et al.
AIDS (London, England)|November 15, 2005
Absence of association between MDR1 genetic polymorphisms, indinavir pharmacokinetics and response to highly active antiretroviral therapyCéline Verstuyft, Fabienne Marcellin, Laurence Morand-Joubert, et al.
European Journal of Cancer (Oxford, England : 1990)|June 19, 2017
First-in-human phase I study of oral S49076, a unique MET/AXL/FGFR inhibitor, in advanced solid tumoursJordi Rodon, Sophie Postel-Vinay, Antoine Hollebecque, et al.
CPT: Pharmacometrics & Systems Pharmacology|November 9, 2021
Population pharmacokinetics of liposomal irinotecan in patients with cancer and exposure-safety analyses in patients with metastatic pancreatic cancerKarl Brendel, Tanios Bekaii-Saab, Patrick M Boland, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
CPT: Pharmacometrics & Systems Pharmacology|October 28, 2025
The Evolving Role of In Vitro-In Vivo Correlation in Model-Informed Drug Development: A Multi-Stakeholder PerspectiveMarylore Chenel, Sylvain Fouliard, Emma Hansson, et al.
Clinical Pharmacokinetics|March 3, 2007
Are population pharmacokinetic and/or pharmacodynamic models adequately evaluated? A survey of the literature from 2002 to 2004Karl Brendel, Céline Dartois, Emmanuelle Comets, et al.
AIDS (London, England)|November 15, 2005
Absence of association between MDR1 genetic polymorphisms, indinavir pharmacokinetics and response to highly active antiretroviral therapyCéline Verstuyft, Fabienne Marcellin, Laurence Morand-Joubert, et al.
European Journal of Cancer (Oxford, England : 1990)|June 19, 2017
First-in-human phase I study of oral S49076, a unique MET/AXL/FGFR inhibitor, in advanced solid tumoursJordi Rodon, Sophie Postel-Vinay, Antoine Hollebecque, et al.
CPT: Pharmacometrics & Systems Pharmacology|November 9, 2021
Population pharmacokinetics of liposomal irinotecan in patients with cancer and exposure-safety analyses in patients with metastatic pancreatic cancerKarl Brendel, Tanios Bekaii-Saab, Patrick M Boland, et al.
Pageof 2